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Suboptimal sedation (over- and undersedation) of intensive care patients has been
associated with adverse patient outcomes and in prolonged stay in hospital, leading
to elevated treatment costs.
Several depth-of-anesthesia monitors have been tested for assessing the level of
sedation. However, their safety and effectiveness has not been validated for regula-
tory authorities. To address the need for improved sedation monitoring, a novel
measurement parameter called Responsiveness Index (RI) was developed by GE
Healthcare in collaboration with Edinburgh Critical Care Research Group. The
parameter quantifies patient’s level of responsiveness from frontal electromyogram
signal. The use of RI as an adjunct to other sedation practices is assumed to guide
the nurses to administer sedatives according to patient’s needs.
In this study, patient data from a randomized controlled pilot trial were analyzed
in order to compare RI-augmented sedation monitoring to the current practice.
The compared variables were RI values, incidences of deep sedation, and patient
outcomes. As a secondary analysis, two patient subgroups in which the effects of
RI monitoring were assumed to be most influential were analyzed.
The sample size in this study was small, and statistically significant results were
not discovered. However, a trend was found indicating that patients who received
RI-augmented sedation monitoring were more responsive, reached high states of
responsiveness faster, and spent less time mechanically ventilated during the in-
tervention period. Additionally, the patients in the RI-augmented group were
significantly more responsive and received less analgesics when only the less re-
sponsive patients at baseline were analyzed. The results are promising, but a
multicenter trial is needed in order to validate the safety and effectiveness of RI.
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Tehohoitopotilaiden suboptimaalinen sedaatio (liiallinen ja riittämätön sedaatio) on
yhteydessä huonoihin potilaiden hoitotuloksiin ja pitkittyneisiin sairaalajaksoihin
johtaen lisääntyneisiin hoitokustannuksiin.
Useita anestesian syvyyttä mittaavia monitoreita on testattu teho-osastopotilaiden
sedaatiotasojen seurannassa, mutta niiden turvallisuutta ja tehokkuutta ei ole
asianmukaisesti validoitu sääntelyviranomaisille. Vastatakseen kehittyneemmän
sedaatiomonitoroinnin tarpeeseen, GE Healthcare on kehittänyt yhteistyössä Edin-
burghin tehohoidon tutkimusryhmän kanssa Responsiveness Index (RI) -parametrin.
RI kvantifioi potilaan responsiivisuustason otsan elektromyografiasignaalista. Ole-
tuksena on, että RI yhdessä muiden sedaatiokäytäntöjen kanssa voisi auttaa hoitajia
annostelemaan sedatiiveja potilaan tarpeiden mukaan.
Tässä työssä analysoitiin potilasdataa, joka oli kerätty satunnaisotetusta vertailu-
kokeesta. Kokeessa verrattiin RI:llä täydennettyä sedaatiomonitorointia nykyiseen
hoitokäytäntöön. Ryhmiä vertailtiin seuraavien muuttujien osalta: RI arvot, syvän
sedaation esiintyvyys ja potilaiden hoitotulokset. Jälkianalyysissä tarkasteltiin
kahta potilaiden alaryhmää, joissa RI-monitoroinnin vaikutuksen odotettiin olevan
tehokkain.
Analyysin perusteella vaikutti siltä, että potilaat joita hoidettiin RI:n kanssa oli-
vat responsiivisempia, tulivat responsiivisiksi nopeammin ja viettivät vähemmän
aikaa mekaanisesti ventiloituina interventiojaksolla. Nämä tulokset eivät kuiten-
kaan olleet tilastollisesti merkittäviä johtuen pienestä otoskoosta. RI-monitoroidut
potilaat olivat merkittävästi responsiivisempia ja saivat merkittävästi vähemmän
kipulääkkeitä, kun vain lähtötilanteessa vähemmän responsiiviset potilaat analysoi-
tiin. Tulokset ovat lupaavia, mutta usean sairaalan kattava tutkimus suuremmalla
otoskoolla tarvitaan validoimaan RI-monitoroinnin turvallisuus ja tehokkuus.
Avainsanat: sedaatiomonitorointi, teho-osasto, responsiivisuus
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Terms, symbols and abbreviations
Terms
Agitation Psychological and physical restlessness
Amnesia Loss of memory caused by disease or physical or psycho-
logical trauma
Analgesia A relief from pain
Anesthesia A temporary state of uncosciousness
Anesthetic A drug used to induce anesthesia
Analgesic A drug used to provide analgesia
Analgo-sedation A strategy that treats pain and achieves sedation at the
same time
Anterograde amnesia A condition in which events that occurred after the onset
of amnesia cannot be recalled and new memories cannot
be formed
Anxiolysis Sedation or hypnosis used to reduce anxiety, agitation
or tension
Apnea Transient cessation of respiration
Ataxia A set of neurological disorders that affect co-ordination
Benzodiazepine Any of a family of minor tranquilizers that act against
anxiety and convulsions; and produce sedation and mus-
cle relaxation
Bispectral Index One of a number of technologies used to monitor the
depth of anesthesia by an algorithmic analysis of the
electroencephalogram
Brainstem Posterior part of the brain joining structurally continu-
ously with spinal cord which provides the main motor
and sensory neural excitation to the face and neck
Bradycardia Slow heart rate
Bronchoscopy Test to diagnose lung disease and view the airway
Constipation A condition in which bowel movements are infrequent or
incomplete
Cortical Involving or resulting from the action of brain’s outer
layer of neural tissue
Deep sedation A state where the patient does not respond to verbal
stimulation
Delirium A more or less temporary disorder of the mental faculties,
as in fevers, disturbances of consciousness, or intoxica-
tion, characterized by restlessness, excitement, delusions,
hallucinations, etc.
ix
Electromyogram A graphic record of the electric currents associated with
muscular action
Encephalitis A virus causing brain inflammation
Encephalopathy Brain disease or malfunction of the brain
Endotracheal tube A tube inserted into the airways to provide mechanical
ventilation
Enteral tube A common name for feeding tube used for patients who
cannot obtain nutrition by mouth
Entropy measurement A device to measure hypnosis in anesthesia
Epileptic seizure A condition caused by excessive or synchronous neuronal
activity in the brain
Extubation The removal of patient from mechanical ventilator
Frontal electromyography Refers to electromyography which is measured from upper
facial muscles
Glabellar tap A tap on the glabella (space between eyebrows and above
the nose) to test the glabellar tap reflex
Hemodynamic The branch of physiology dealing with the forces involved
in the circulation of the blood
Hypotension Low blood pressure
Hypoxia Unadequate oxygen supply
Immuno-compromised patient Patient whose immune system ability to fight infectious
disease is compromised or absent
Inhibitory neurotransmitter A substance that carries a signal from one nerve cell to
another and has an inhibitory effect
Inter-rater reliability Degree of agreement among raters
Intracerebral Situated or occuring within the brain
Intravenous Method to administer drugs directly into a vein
Intubation Procedure involving the insertion of the tube used in
mechanical ventilation
Light sedation A state in which patient responds to verbal stimulation
Meningitis Inflamation of protective brain membranes
Multicenter trial A clinical trial performed at more than one clinic
Myocardial infarction Occurs when myocardial ischemia exceeds a critical tresh-
old and may result in irreversible cell damage to the heart
Myocardial ischemia A blockage in the coronary arteries causing decrease in
blood flow to the heart muscle
Nasogastric tube A tube inserted through the nose to stomach to provide
nutrition support
xNausea A feeling of unease and discomfort of stomach
Neuromuscular blocking agent A drug which blocks the muscular functions
Non-parametric method A statistical method which does not make assumptions
about distribution
Opiate Any of several synthetic compounds having effects similar
to natural opium alkaloids and their derivatives
Oxygen desaturation Decrease in blood oxygen concentration
Patient State Index EEG based measure intended to monitor the state of the
brain
Patient ventilator dyssynchrony Occurs when a patient’s spontaneous respiratory efforts
are no longer in synchrony with the mechanical ventilator
Pivotal trial A trial used to make specific claims about efficacy and
safety of the device
Post-traumatic stress disorder A mental health condition caused by traumatic event
Prone positioning A body position, in which one lies chest down
Sedation The calming of mental excitement or abatement of phys-
iological function, especially by the administration of a
drug
Sedative A drug which is used to conduct sedation
Self-extubation An unwanted removal of critical tubes performed by the
patient
Status epilepticus A state where epileptic seizure lasts more than 5 minutes
or where the epileptic seizures occure with high frequency
Suboptimal sedation Over- or undersedation
Tracheostomy Providing breathing support with a tube through opening
at the front of the neck
Urinary retention Inability to fully empty the bladder
Vascular catheter A tube inserted to patient’s vein allowing easy access to
the bloodstream
xi
Symbols
χ2 Chi-squared distribution
E Expected number of events
g Weighting function of RI
n Number of samples
N Number of filtered power value samples
O Observed number of events
p p-value
PF Filtered fEMG power value
S Scaling function of RI
t Time
X2 Chi-square
Abbreviations
AIDS Acquired immune defiency syndrome
APACHE Acute Physiological and Chronic Health Evaluation
BIS Bispectral Index Scale
CCI Charlson Comorbidity Index
EEG Electroencephalogram
EMG Electromyogram
fEMG Frontal electromyogram
FDA US Food and Drug Administration
ICU Intensive care unit
ICU-LOS Length of stay in ICU
IHI Institute for Healthcare Improvement
i.v. Intravenous
LOS Length of stay in hospital
NMBA Neuromuscular blocking agent
PSI Patient State Index
PTSD Post-traumatic stress disorder
RI Responsiveness Index
RASS Richmond Agitation–Sedation Scale
RSS Ramsay Sedation Scale
SOFA Sequential Organ Failure Assessment
VAP Ventilator-associated pneumonia
11 Introduction
1.1 The economic burden of intensive care
Intensive care units (ICUs) are designed to treat and monitor critically ill and unstable
patients. The patients admitted to the ICUs are the sickest in the hospital. They
typically have failures in several organ systems and may be unable to breathe on
their own [1]. The primary principle of intensive care is to aggressively support the
patient’s organ systems, not to perform complex interventions or investigations [2].
For example, many patients admitted to an ICU require mechanical ventilation to
assist or replace spontaneous breathing [3]. Patients are admitted to the ICU for
multiple reasons, for instance to treat severe illness or to monitor the patient after
surgery or an accident [4].
The demand for intensive care services has been increasing worldwide as a result
of aging population and the availability of more complex care procedures [5]. The
United States has the highest number of ICU beds in the world [6], and more than
five million people are admitted to the ICU annually [7]. According to The Society
of Critical Care Medicine, annual critical care medicine costs in the US rose between
2000 and 2005 from $56.6 to $81.7 billion (44%) and represented 13% of all hospital
costs [7]. Yet the costs are still increasing as in 2013 the critical care accounted
for 20% of all hospital costs and 1% of US gross national domestic product [8]. In
order to reduce ICU costs, the attention has recently focused on assessing patients
with prolonged length of stay (LOS) in the ICU as well as strategies to improve
quality of treatment. A study by Yaseen Arabi and colleagues found that patients
with prolonged ICU stay formed only 11% of patients, but utilized 45% of ICU days.
The pressure to decrease LOS in ICUs is not only about reducing costs, but also
to tackle the adverse effects caused by prolonged stay. Prolonged ICU stay can
adversely have a negative impact on patient’s health status, since it increases the risk
of infection and complications, and possibly even mortality. Operationally, increased
LOS impacts also upon ICU bed availability, and leads to longer waiting times. [9]
ICU patients are often agitated and require sedatives to calm from mental
distress. One way to decrease lenght of stay in intensive care unit (ICU-LOS) is to
pay attention to sedation monitoring protocols and practice. As reported by Hughes
and colleagues, suboptimal sedation (over- and undersedation) can increase risk of
complications leading to elevated treatment costs [10]. For example, oversedation
has been associated to lead to prolonged time in the mechanical ventilator, which
has been shown to increase the risk of infections, and therefore, raise the costs of
treatment [11]. Although valid clinical tools exist for monitoring the depth of sedation,
they often rely on subjective assessments and require stimulating the patient, and
therefore, may disturb the sleeping pattern. Several technologies for monitoring
sedation level with electroencephalogram (EEG) analysis exist, but these methods
were developed primarily for depth of anesthesia monitoring, and their validity for
sedation monitoring is uncertain.
21.2 Responsiveness monitoring
To address the unmet need for improved sedation monitoring, a collaborative research
programme between GE Healthcare and Edinburgh Critical Care Research Group
developed Responsiveness Index (RI) – a novel parameter to quantify patient’s level
of responsiveness. The parametrs generates a responsiveness number (RI value), with
a range of 0 (unresponsive) to 100 (highly responsive), from frontal electromyogram
(fEMG) signal, which may help the caregiving nurse to adjust sedative medication
according to the patient’s needs. The use of Responsiveness Index as an adjunct
to current clinical practices is expected to improve a range of patient-based and
economic outcomes, including ICU-LOS.
1.3 Objectives of the study
This study looks to assess the safety and effectiveness of continuous Responsiveness
Index-augmented sedation monitoring during early ICU care as a nurse decision-
support tool. Data were analyzed from a randomized controlled pilot trial comparing
sedation management using a protocol based on responsiveness monitoring against
the current practice.
The main objective of this study was to test whether monitoring the patient
with RI during early ICU care will decrease the period spent less responsive (RI
< 20) without excess adverse events. The secondary objectives were to investigate
whether monitoring the responsiveness of the patient reduces the incidences of deep
sedation (a state where the patient does not respond to verbal stimulation); reduces
the time to reach RI ≥ 20 and light sedation (a state where patient responds to
verbal stimulation); and improves a range of patient-based outcomes.
In the primary analysis, all the patients recruited to the study were analyzed. In
the secondary analysis, two patient subgroups were studied in which the effects of
RI monitoring were expected to be most influental. The first subgroup consisted of
patients with RI < 20 at the start of monitoring and the second subgroup consisted
of patients who were deeply sedated at the start of monitoring. The objective of the
secondary analysis was to test whether or not the patients in these subgroups were
more affected by the study protocol. As this study was a pilot trial, the secondary
analysis was performed in view of inclusion criteria for a pivotal trial. A pivotal trial
is typically a large multicenter trial, which is used as the primary proof of safety and
effectiveness of the device for regulatory authorities [12, 13].
This thesis is a part of a larger effort to provide clinical evidence to support the
regulatory clearance from the US Food and Drug Administration (FDA). Due to the
reason that the data were gathered from a pilot trial, and therefore, the sample size
was small, statistically significant results were not expected to be found. However,
rather than looking for statistically significant results between the compared variables,
the aim was to find trends and provide descriptive statistics which could indicate that
the tested protocol is feasible for a pivotal trial. By using the results as a reference,
recommendations for the pivotal trial are given in Chapter 6.4.
32 Clinical background
During the past years, critical care researchers and physicians have started to recognize
the adverse effects caused by suboptimal sedation. The recent publications in the field
of critical care medicine suggest that agitation, as well as delirium and pain, should
be evaluated systematically with evidence-based strategies [14, 15]. Although valid
tools and strategies exist for sedation management, they are not widely used [16, 17].
This chapter will present the clinical background behind sedation and analgesia,
the adverse effects caused by suboptimal sedation, and the current sedation man-
agement practices with their limitations. In addition, the severity-of-illness scores,
which are used in this study to compare baseline differences, are briefly introduced
at the end of this chapter.
2.1 Sedation and analgesia in the ICU
Critically ill patients – especially those receiving mechanical ventilation and other
life-supporting interventions – are treated with sedatives as a standard procedure
to reduce agitation [18]. Sedation is administered to reduce patients’ discomfort
and agitation during painful or distressing procedures that are frequently performed
during ICU treatment. Sedation also helps the patient to cope with the emotional
effects caused by critical illness experience. Agitation has been shown to be a
commonly existing emotional state among ICU patients. Rowe and Fletcher have
demonstrated that it occurs at least once in 71% of medical-surgical ICU patients
and this is notably true for mechanically ventilated patients, who make up a major
proportion of all ICU treated cases [19].
Agitation causes sympathetic stress response. If left untreated, the stress response
can lead to negative prolonged acute consequences [10]. Most common symptoms
caused by untreated stress response are difficulty of breathing, patient-ventilator
dyssynchrony, elevated blood pressure and heart rate, combative behavior and post-
traumatic stress disorder (PSTD). [20]
There are multiple factors causing agitation to the patient in an ICU setting.
Commonly, agitation is a result of intractable or untreated pain, mechanical ventila-
tion, invasive procedures, sleep deprivation, prone positioning, adverse drug effects,
and alcohol and drug withdrawal [20]. In addition, unfamiliar environment, loss of
self-control, inability to communicate, and isolation may have an effect in causing
agitation [21]. Identifying the relationship between agitation and causative factors
can be ambiguous, because they are often multifactorial (see Figure 1).
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Figure 1: Causes of agitation. Modified from the original figure by Sessler and
Muzevinch [3].
Agitation is inextricably linked to pain and delirium [22]. This means that pain
and delirium can cause agitation and vice versa (see Figure 2). Additionally, treating
agitation with doses of sedatives that alter consciousness may cause delirium [23].
5Figure 2: Connection between pain, agitation and delirium [22].
When pain contributes to development of agitation, agitation follows from the
sensation of pain. Sedation aims to treat the anxiety component of pain, not the
pain itself. [10] Attempts to control pain through only sedatives are inneffective and
may lead to oversedation. Therefore, the first aim of analgo-sedation, a treatment
focusing on pain and agitation simultaneously, is to ensure proper analgesia, and
then control agitation [24]. Opiates, such as alfentanil and morphine, are the most
frequently administered analgesics to treat pain in ICU setting. Even though they
are effective in treatment of pain, opiates have significant side effects. They can cause
respiratory depression, constipation, urinary retention, nausea, and confusion. [25]
The balance between beneficial analgesia and adverse effects in opioid use is the
limiting factor when conducting pain therapy [26].
Treating agitation with sedatives in a safe manner can be challenging. Sedatives
have been categorized as "high-alert" drugs by the US based Institute for Health-
care Improvent (IHI). The category includes medicines which have been defined as
"drugs that have the highest risk of causing injury when misused". [20, 27] Therefore,
understanding the properties and limitations of sedatives is important when conduct-
ing sedative therapy. Bun and Dunn have described the ideal sedative as follows:
6"The ideal sedative has been described as one that works rapidly; provides anxiolysis,
sedation, amnesia, or a combination of these; allows quick emergence when stopped;
permits easy administration and adjustment of dosage; produces no active metaboli-
ties, significant adverse effects, or drug-drug interactions; and is inexpensive." They
note that no sedative meets all these criteria and clinicians must therefore choose
the right sedative according to the patient’s condition [28]. Common and widely
used sedatives are propofol and midazolam [19], which will be briefly presented in
the following sections.
2.1.1 Propofol
Propofol is a sedative with hypnotic properties and it has a rapid onset and offset of
action [29]. Because the concentration in blood drops quickly after the administration
has stopped, it can be used in patients who need rapid awakening [28]. The rapid
onset and offset allow greater control over the depth of sedation [30]. Propofol
provides adequate sedation with a similar proportion to midazolam, but the recovery
rate is faster with the patients for whom propofol is administrated [29].
Table 1: Therapeutic indications and possible adverse effects reported by the manu-
facturer for propofol [31].
Therapeutic indications Adverse effects
Short-acting intravenous general anes-
thetic used for:
• induction and maintenance of general
anesthesia;
• sedation for diagnostic and surgical
procedures, alone or in combination
with local or regional anesthesia; and
• sedation of adult ventilated patients.
Common adverse events are:
headache in the recovery phase;
bradycardia; hypotension; transient
apnea during induction; nausea and
vomiting during recovery phase; and
local pain on induction.
2.1.2 Midazolam
Midazolam is a benzodiazepine, which causes sedation and anterograde amnesia by
affecting the inhibitory neurotransmitters. It is recommended for treatment of acute
agitation due to its rapid onset (two to five minutes). Midazolam has been shown to
accumulate and cause prolonged sedation in the ICU, hence it is not recommended
for longer use than 24 hours [28]. A literature review conducted by Audrey Shafer
on complications of sedation with midazolam in the ICU highlight that continuous
infusion of midazolam is an effective way to sedate ICU patients, but it may cause
complications. The reported complications were development of tolerance particulary
in longer-term infusions, prolonged sedation due to accumulation of the drug, and
cluster of symptoms that emerge during withdrawal from the drug. [32]
7Table 2: Therapeutic indications and possible adverse effects reported by the manu-
facturer for midazolam [33].
Therapeutic indications Adverse effects
For sedation by continuous infusion in
patients in intensive care.
The following undesirable effects have
been reported (very rarely) to occur
when midazolam is injected: confusional
state; euphoric mood; hallucinations;
paradoxical reactions such as agitation;
involuntary movements; prolonged se-
dation; decreased alertness; sleepiness;
headache; dizziness; ataxia; cardiac ar-
rest; respiratory depression; and antero-
grade amnesia.
2.2 Suboptimal sedation
As noted earlier in this Thesis, suboptimal sedation is associated with adverse events
and worse clinical outcomes, leading to an increased ICU-LOS [10, 19].
Undersedation can lead to multiple undesirable effects, such as self-extubation
or even combatitive behaviour against the care providers. It can occur in critically
ill patients with as high rates as 75% of all patient during ICU stay. Most common
responses to undersedation are self-removal of critical tubes and vascular catheters,
which place the patient in danger from loss of treatment devices. [3] Mion and
colleagues investigated the patient-initiated device removal in ICUs and found that
self-removal of devices occured in 22 incidences out of 1000 patient-days [34]. In
addition to device removal and combative behaviour, undersedation can lead to
intense stress response [3], hence affect the patient comfort. In the worst-case
scenario, the mental stress resulting from being consciouss through painful and
terrifying procedures can lead to post-traumatic stress disorder [35].
Oversedation is a general problem in the ICU. A systematic review on studies of
sedation practices conducted by Jackson et al. showed that substantial number of
suboptimal sedation incidences were reported in all reviewed studies, with tendency
to oversedation [36]. Oversedation can hamper the recovery by causing delirium and
immobility, and therefore, lead to prolonged LOS. [20] Another important consequence
of oversedation is the supression of spontaneous breathing reflex [37], which can delay
the weaning from ventilator and thus, increase the duration of mechanical ventilation.
In addition, oversedated patients are not able to influence their own treatment, as
they are unable to interact with their family and environment.
Oversedating patients can lead to a vicious cycle (see Figure 3). The excessive
sedation creates a dynamic loop that can aggravate muscle waisting, thus lead to a
prolonged time in mechanical ventilator [38]. The additional time spent in mechanical
ventilator has been shown to increase the risks of lung injury and infections [11],
which result in unimproving health status of the patient, and therefore, may lead
nurses to increase sedation infusion.
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Figure 3: Vicious cycle of oversedation. Modified from Vasilevskis et al. [38].
Even though oversedation can have severe consequences on the patient’s health,
visually oversedated patients look peaceful and comfortable, and deeply sedated states
can visually mimic peaceful sleep. Therefore, the care-giving nurses can perceive
oversedation as kindness towards the patient. [39]
It must be noted that some conditions and situations may require deeper sedation
for depression of consciousness to induce a state where the patient is not easily
arousable, but still responds to painful stimulation [40]. Examples of conditions
where deep sedation is required are ventilator dyssynchrony secondary to hypoxia,
hyperactive airway disease infuriated by anxiety, and very uncomfortable procedures
such as inserting the endotracheal tube or bronchoscopy. [20]
Achieving balanced sedation is particularly challenging in mechanically ventilated
patients, as a review by Jackson and the research team highlighted that potentially 40–
60% of mechanically ventilated patients are oversedated [36]. Being on a mechanical
9ventilator can cause strong feeling of agitation, as the patient is often aware that he
or she is in a life-threatening situation without control or means to communicate [41].
As oversedation prolongs the time spent in a mechanical ventilator, it can lead to
ventilator-associated pneumonia (VAP). VAP is the most common hospital-acquired
infection among ICU patients. Between 10% and 20% of patients who received more
than 48 hours of mechanical ventilation will develop VAP. It may lead to significant
morbidity, a two-fold mortality rate and elevated costs. In a study by Safdar and
colleagues, the research team reported that VAP increased mean ICU-LOS for 6.1
days and added additional hospital costs over $10 000 per patient. [11]
2.3 Sedation management
Modern practical guidelines stress the importance of adopting patient-focused ap-
proach in sedation management, which aims to treat the patient with the lowest
effective dose of drugs. Proper sedation management controls the following elements:
monitoring the depth of sedation; treating the patient with correct sedative; assuring
that the subject is kept on the lightest level of sedation as possible; and establishing
goals of sedative therapy. [3] At present, sedation management is typically imple-
mented through sedation protocols, which include clinical assessments linked to
decision-making strategies, and sedation holds.
Adopting sedation management protocol has been proven to lead to better patient
outcomes. In 2010, Scrobik and colleagues published results from an intervention
study, in which the research team examined the effects of using a sedation management
protocol. The data were collected from adult patients admitted to an ICU during
two periods: before (610 patients) and after (604 patients) the implementation of the
protocol. Patients who received protocol based care had a lower 30-day mortality
risk than those who had received non-protocolized care. They also spent less time in
mechanical ventilator, and medication induced coma rates were lower. [23]
As suboptimal sedation has a significant impact on patient outcomes, therefore
the aim of sedation monitoring is to avoid incidences of both over- and undersedation.
Sedation monitoring is mostly executed through clinical assessments which are linked
to decision-making strategies to titrate the sedatives according to patient’s needs.
The clinical assessments are performed by observing the behaviour of the patient by
using structured sedation scales. When applying these scales, the care provider gives
different types of standard stimuli and assesses the patient’s response. The arousal
level tested typically ranges from alert to comatose. [3] The commonly used sedation
scales are Richmond Agitation-Sedation Scale (RASS) and Ramsay Sedation Scale
(RSS).
2.3.1 The Richmond Agitation-Sedation Scale
According to Sessler and colleagues, the Richmond Agitation-Sedation Scale (RASS)
is the most valid and reliable sedation assessment tool for adult ICU patients to
monitor the depth of sedation [3]. RASS was developed at Commonwealth University
in Richmond, USA by a team of physicians, nurses and pharmacists [42]. It is a
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ten-point scoring system based on the response to the assessor’s voice and to physical
stimulation. The range of the scale varies from –5 (unrousable) to +4 (combative).
A score of 0 signifies that the patient is alert and calm. [43] RASS has the advantage
of separating verbal from physical stimulation, allowing the patient’s level of arousal
to be graded on the basis of the stimulus [44].
In 2003, Ely and the research team discovered that RASS has excellent inter-rater
reliability by analyzing 290 paired observations by nurses. Additionally they tested
the face validity of RASS via survey of 26 critical care nurses, and the results showed
that 92% agreed or strongly agreed with the RASS scoring system. The same survey
demonstrated 81% of the nurses agreed or strongly agreed that RASS provided a
consensus for goal-directed delivery of sedatives. [44]
Table 3: Richmond Agitation-Sedation Score [42].
Score Term Description
+4 Combative Overly combative or violent, immediate danger to
staff
+3 Very agitated Pulls on or removes tubes or catheters or has ag-
gressive behavior toward staff
+2 Agitated Frequent nonpurposeful movement or patient ven-
tilator dyssynchrony
+1 Restless Anxious or apprehensive but movements not ag-
gressive or vigorous
0 Alert and calm
–1 Drowsy Not fully alert, but has sustained (more than 10
seconds) awakening, with eye contact/eye opening
to voice
–2 Light sedation Briefly (less than 10 seconds) awakens with eye
contact to voice
–3 Moderate sedation Any movement (but no eye contact) to voice
–4 Deep sedation No response to voice, but any movement to physical
stimulation
–5 Unarousable No response to voice or physical stimulation
The RASS scoring is done in accordance with the following procedure [42]:
1. Observe patient. Is patient alert and calm (score 0)?
2. Does patient have behavior that is consistent with restlessness or agitation
(score +1 to +4 using the criteria listed above)?
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3. If patient is not alert, in a loud speaking voice state patient’s name and direct
patient to open eyes and look at speaker. Repeat once if necessary.
(a) Patient has eye opening and eye contact, which is sustained for more than
10 seconds (score –1).
(b) Patient has eye opening and eye contact, but this is not sustained for 10
seconds (score –2).
(c) Patient has any movement in response to voice, excluding eye contact
(score –3).
4. If patient does not respond to voice, physically stimulate patient by shaking
shoulder and then rubbing sternum if there is no response to shaking shoulder.
(a) Patient has any movement to physical stimulation (score –4).
(b) Patient has no response to voice or physical stimulation (score –5)
2.3.2 The Ramsay Sedation Scale
The Ramsay Sedation Scale (RSS) was the first widely utilized sedation scale for
ICU patients [3]. It was first described by Ramsay et al. in 1947 and it was designed
to test patient’s rousability [26, 45]. Now it is one of the most widely used sedation
scale [46]. The Ramsay Sedation Scale has six different levels measuring the patient’s
rousability from conscious and agitated state (level 1) to unresponsive (level 6). The
stimulus was designed not to be painful, and it should not rouse a sleeping patient
excessively to impede normal sleeping pattern. [26]
De Jonghe and colleagues have stated that RSS inhibits a satisfactory inter-rater
reliability and high correlation with other sedation scales [47]. However, compared
to RASS, RSS does not make a clear distinction between levels of agitation.
Table 4: The Ramsay Sedation Scale [26].
Level Characteristics
1 Patient awake, agitated or restless
2 Patient awake, co-operative, orientated and tranquil
3 Patient drowsy, with response to commands
4 Patient asleep, brisk response to glabellar tap or loud auditory stimulus
5 Patient asleep, sluggish response to stimulus
6 Patient has no response to firm nailbed pressure or other noxious stimuli
The Ramsay Sedation Scoring is done by using the following steps: observation of behaviour
(score 1 or 2), followed (if necessary) by assessment of response to voice (score 3), followed
(if necessary) by assessment of response to loud auditory stimulus or light glabellar tap
(score 4 to 5). [26]
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2.3.3 Sedation holds
Sedatives can be administered by continuous infusion or as boluses when required.
The most common way is to use continuous infusion, which provides a steady sedation
with less episodes of occasional agitation. [19] However, continuous infusion may
lead to prologed mechanical ventilation and ICU stay. In addition, the patient’s
neurological status cannot be accurately monitored. A study by Kollef and the
research team revealed that the duration of mechanical ventilation was significantly
longer for patients receiving continuous infusion of sedatives as opposed patients not
receiving continuous infusion of sedatives. They suggested that strategies targeted
at reducing the use of continuous infusion could decrease the duration of mechanical
ventilation for some patients. [48]
One way to tackle the adverse effects caused by continuous infusion is to put the
administration of sedatives on hold by decreasing the level of sedation slowly until
patient is responsive. [49, 50] The sedation interruptions allow clinicians to find the
optimal sedation level while maintaining patient comfort [49].
Multiple studies have demonstrated the benefits of using daily sedation holds
as standard practice in the ICU. For example, in 2000, Kress et al. compared
standard practice without sedation scoring or pre-defined protocols against using
daily sedation holds in ICU patients. The authors found a significant decrease in
duration of mechanical ventilation and ICU-LOS. Additionally, the patients receiving
daily sedation holds did not have abnormally high rate of adverse events. [49]
In a study conducted by Girard and the research team in 2008, sedation holds
were shown to significantly decrease in duration of mechanical ventilation, ICU-LOS
and hospital LOS. Additionally, they found decrease in mortality rate after one year
of the study. [51]
2.3.4 Limitations of current sedation practices
Protocolized sedation management, including sedation scales and daily interruption
of sedatives, have been proven to lead to better patient outcomes. These protocols
have been demonstrated to shorten the ICU lenght of stay, reduce the time spent in
mechanical ventilator, and minimize the effects of sedative accumulation. [52]
Even though the sedation protocols have been demonstrated effective, they are
not widely used. A survey study conducted by Tanios and the research group showed
that the daily sedation interruption was used only by 40% of critical care clinicians
and 36% did not have sedation management protocol in use. Protocols were not
followed for the following reasons: no physician order (35%), lack of nursing support
(11%), and fear of oversedation (7%). [16]
Sedation guidelines and protocols may be ignored unintentionally by the physicians.
In 2000, Slomka and colleagues investigated the clinicians values and perceptions on
use of clinical practice guidelines for sedation. The researchers came to a conclusion
that physicians may think that they are following sedation guidelines when they are
not. The research showed that 69% of physicians reported following guidelines, but
in reality their actual adherence was only 20%. [17]
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The problem with clinical scoring systems is that they are subjective, and thus, can
be subjected to variability between interpreters. According to Weinert and colleagues,
the subjective assessments are affected by social, personal, and professional factors [53].
Additionally, they do not discriminate deeper levels of sedation clearly, and require
stimulating the patient, hence can cause sleep disruption and distress [54].
In addition, the choise of sedation management protocol can also be challenging.
There is no universally accepted sedation management protocol and selecting the
appropriate one can depend on multiple factors. Adopting a certain sedation manage-
ment protocol can be affected by regional preferences, patient history, institutional
bias and patient and clinician variability [10].
2.4 Severity-of-illness scores
Severity-of-illness scores have been designed compare the ICU patients’ health status.
These scores are calculated from physiological variables measured typically within
the first 24 hours of ICU stay. In research, the severity of illness scores are often
used for risk adjustment in ICU outcome studies [55]. They can also be used for
quality assurance purposes in randomized controlled trials to determine whether
the compared groups are similar in terms of therapy regimen [56]. Commonly
used severity-of-illness scores are Acute physiological and chronic health evaluation
(APACHE II), The Sequential Organ Failure Assessment (SOFA) score, and Charlson
Comorbidity Index (CCI), which are briefly introduced in the following subchapters.
2.4.1 Acute physiological and chronic health evaluation
Acute physiological and chronic health evaluation (APACHE II) is a severity-of-illness
classification system, which is used in the ICU to help to estimate the prognosis
of the patient. [57] In APACHE II, there are 12 physiological variables and the
effects of age and chronic health status are incorporated directly into the model. The
worst recorded value, for every physiological variable during first 24 hours after ICU
admission together with the weighted chronic health status and age, are used to form
a single increasing score with a range from 0 to 71. [58]
In APACHE II scoring system, the patient receives points depending on the
difference between the measured physiological value and normal range defined by
the system. It is performed during the first 24 hours after the ICU admission. If the
measured physiological value is in the normal range, the patient will receive 0 points,
while the maximum points for high abnormality are +4. The investigated variables
are listed in table 5. [57]
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Table 5: APACHE II physiological variables with definitions/clarifications. Modified
from a publication by Knauss et al. [57].
Physiological variable Definition or clarification
Body temperature Measured from rectal in celcius
Arterial pressure Average blood pressure
Heart rate Ventricular response
Respiratory rate Non ventilated or ventilated
Oxygenation Concentration of oxygen in blood
Arterial pH Acidity of arterial blood
Sodium (serum) Amount of sodium in blood serum
Potassium (serum) Amount of potassium in blood serum
Creatinine (serum) Amount of creatine in blood (patients receiving
chronic dialysis get double points)
Hematocrit Volume percentage of red blood cells in blood
White blood count Number of white blood cells in blood
Glasgow coma score A neurological scale recording the conscious state
of patient
Chronic health points are given if the patient has a history of severe organ
insufficiency or is immuno-compromised. The points are given as follows: two points
for elective postoperative patient with immuno-compromise or history of severe organ
insufficiency, and five points for nonoperative patient or emergency postoperative
patient with immuno-compromise or severe organ insufficiency. [57] Patients will also
receive points depending on age according to Table 6.
Table 6: Points given based on age [57].
Age (yrs) Points
≤44 0
45–54 2
55–64 3
65–74 5
≥75 6
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2.4.2 Sequential Organ Failure Assessment score
The Sequantal Organ Failure Assessment (SOFA) scoring is used to analyze patient’s
organ dysfunction or failure, and it can be used to evaluate morbidity and predict
mortality [59]. It measures the function of six major organ systems; cardiovascular,
respiratory, renal, hepatic, central nervous system, and coagulation [60]. Each system
gets a score from 0 (normal) to 4 (most dysfunction), thus the maximum score is
24 [61].
2.4.3 Charlson Comorbidity Index
The Charlson Comorbidity Index uses a total of 22 common conditions (see Table 7)
to predict mortality of the patient. The score of each condition has been weigted
by the relative risk of mortality associated with each disease. The scores for each
disease are summed together to form the index, with a range from 0 (lowest risk of
mortality) to 37 (highest risk of mortality). [62]
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Table 7: Charlson Comorbidity Index variables. Modified from the publication by
Kastner et al. [63].
Condition Definition Score
Myocardial infraction Occurs when blood flow stops to a part of heart
muscle due to a blockage
1
Congestive heart failure A condition in which heart muscle does not pump
blood correctly
1
Peripheral vascular disease Blood vessel disease located outside the heart and
the brain
1
Cerebrovascular disease A condition caused by inadequate supply of blood
to the brain
1
Dementia Set of symptoms including memory loss and gradual
decrease in ability to think
1
Chronic pulmonary disease A set of lung diseases which make the breathing
difficult
1
Connective tissue disease A disease that attacks the core components of con-
nective tissue
1
Peptic ulcer disease A break in the lining of stomach or first part of the
duodenum
1
Mild liver disease Patients with cirrhosis without portal hypertension
or chronic hepatitis (inflammation of the liver)
1
Diabetes A condition which causes the blood sugar levels to
become too high for over a prolonged period
1
Hemiplegia Paralysis of one side of the body 2
Moderate or sever renal dis-
ease
Moderate renal insufficiency includes patients with
high serum creatine levels: severe renal disease in-
cludes patients on dialysis, those who had a trans-
plant, and those with renal failure
2
Diabetes with or end organ
damage
Diabetics whose retina or nerves have damaged 2
Any tumor Patients with solid tumors without spread of cancer 2
Leukemia A cancer of the blood cells 2
Lymphoma A cancer that affects the immune system 2
Moderate or severe liver dis-
ease
Patients with chirrosis and hypotension 3
Metastatic solid tumor A solid tumor which has spread to other parts of
the body
6
AIDS Acquired immune defiency syndrome 6
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3 Technological background
In order to have a regulatory approval for a medical device from the US Food and
Drug Administration, the manufacturer must demonstrate valid scientific evidence
that provides reasonable assurance that the device is safe and effective for its intended
use [64]. The safety and effectiveness is usually demonstrated through pivotal trials.
The pivotal trials are typically large multicenter trials [65] conducted after the study
protocol has been tested with a small sample size in a pilot trial [13].
Many EEG based monitoring systems, such as Bispectral Index Scale, Patient
State Index, and State Entropy, have been studied at ICU environment for monitoring
the depth of sedation. However, according to the FDA, none of them have been
directly indicated or validated to measure the level of sedation of ICU patients [66,
67, 68].
For the purpose of monitoring sedation level of ICU patients, GE Healthcare in
collaboration with Edinburgh Critical Care Research Group has developed Responsive-
ness Index. It is a novel measurement parameter quantifying patient responsiveness
from frontal EMG (fEMG). The Resposiveness Index is hypothised to be an objective
measurement which could help the nurses to titrate sedatives according to patient’s
needs. However, Responsiveness Index has not yet gained regulatory approval from
the FDA, and the pivotal study has not been conducted.
First, this chapter will briefly present the EEG based measures and review the
the most notable studies in which they been tested in the ICU for monitoring the
level of sedation. Second, the basics of Responsiveness Index are summarized. Third,
as this study analyzes the results from a pilot study, common hypothesis tests for
trials with small sample sizes are presented.
3.1 Depth of anesthesia monitors
Electroencephalographic (EEG) signals can be used to quantify the patient’s level
of consciousness. By using mathematical algorithms, the raw EEG signal can be
processed to create a single number from 0 (flat EEG) to 100 (fully alert). The
current EEG based monitoring systems were primarily developed to monitor depth
of anesthesia, not the level of sedation. However, these monitors have been used
to assess level of consciousness of ICU patients, [69] as they offer more objective
measure of sedation level than clinical scoring systems [70]. These monitors also
have the benefit of continuous display of data, which can be used to track unexpected
changes in level of consciousness. [3] The following subchapters will present the EEG
based monitoring systems which have been tested to measure the sedation level of
an ICU patient.
3.1.1 Bispectral Index Scale
Bispectral Index was developed to monitor the level of consciousness in anesthetized
patients [71]. In the United States, it has been indicated to be used as an aid in
monitoring the effects of certain anesthetic agents. The use with certain anesthetic
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agents may be associated with reduction in primary anesthetic use. Additionally, it
may help to guide anesthetic administration, thus reduce incidences of awareness
with recall during anesthesia and sedation. [66]
BIS has been compared to clinical sedation scales in numerous studies. In
a review conducted by LeBlanc and colleagues in 2006, results from 19 of these
studies were summarised. They found that the correlation between BIS and clinical
assessment scores varied between marginal and good. BIS did not correlate well with
clinical assessment of sedation levels in all patients. Additionally, the interindividual
differences increased at deeper levels of sedation. The authors recommend further
studies to evaluate the impact of the BIS monitoring to patient outcomes. [72]
In 2009, Olson et al. studied the effects of BIS augmented sedation monitoring
to patient outcomes in mechanically ventilated neurological patients. The patients
were divided into two groups: patients receiving sedation monitoring with BIS and
Ramsay Sedation Scale (n = 32), and patients receiving sedation monitoring only
with Ramsay Sedation Scale (n = 35). As a result, they found that when BIS was used
in conjunction with RSS as opposed to only using RSS, patients received significantly
less propofol by volume on average during 12 hour period of monitoring (93.5 ml vs
157.8 ml with p < 0.015). Additionally, the patients who received BIS augmented
monitoring, had lower infusion rates and woke up significantly quicker. There were
no undersedation events during the 12 hour monitoring period within either of the
study groups. However, there were no statistical difference noted in Ramsay scores
nor in the distribution of the scores between the two groups. [73] The results suggest,
that using EEG based sedation monitoring with clinical sedation scales may result
in better patient outcomes. However, high electromyographic (EMG) activity has
been shown to cause artefacts to the processed EEG values, leading to increased BIS
values [74].
3.1.2 Patient State Index
According to the FDA, the Patient State Index (PSI) is an EEG based method
intended to measure the state of the brain in the operating room, intensive care
unit or research laboratory [67]. As reported by Drover and Ortega, it has been
specifically designed to provide an indication of sedation and anesthesia levels during
surgery in the ICU. Like BIS, PSI value is derived from EEG signal and it gives a
number from the range between 0 (deeply anesthetised) and 100 (fully awake). [75]
In 2003, Schneider and colleagues evaluated whether the PSI indicates the level of
sedation as measured by Ramsay score in mechanically ventilated ICU patients. As a
result, they found that PSI showed good association with the levels of sedation. [76]
However, not all studies have demonstrated that PSI is a good indicator of
sedation level. In 2011, Caputo and the research team evaluated the PSI in a study
involving 19 ICU patients whose treatment included surgical therapy with continuous
intravenous sedation. In this study, the Ramsay sedation scale and PSI showed poor
correlation, partly due to EMG artefacts. In conculsion, the authors suggested that
clinical assessment by healthcare practitioner is the best way to monitor patient’s
sedation level. [77]
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3.1.3 State Entropy
State Entropy is an EEG based measure indicated in the US for monitoring the
state of the brain and effects of certain anesthetic agents [68]. In 2008, Walsh and
colleagues studied whether or not State Entropy is a valid measure of sedation state in
critically ill patients by comparing it to RSS. The results showed poor discrimination
between different sedation states and in conclusion, the authors stated that fEMG
was a major confounder in the study. [78]
3.2 Responsiveness Index
As presented earlier, no device on the market can reliably measure a patient’s sedation
level. As the devices available were originally designed for measuring the depth of
anesthesia, they were adopted or transferred from the anesthesia setting to the ICU.
Studies regarding the use of BIS, PSI and State Entropy in the ICU setting suggest
that fEMG activity is a major confounder for these algorithms. The reason is that
the frequent arousals typical to the ICU patient increase fEMG activity, and the
frequency bands of EEG and fEMG overlap. [79]
Responsiveness Index uses a different method than EEG based measures to assess
the level of sedation. It is a parameter which quantifies the patient’s responsiveness
from fEMG. It is hypothized that fEMG is useful for measuring the sedation level of
the patient, as it measures the patient’s responsiveness caused by the stimulation
during treatment.
3.2.1 Responsiveness and frontal electromyography
Human body creates various responses to changing emotional states and the face
plays a substantial role in expressing these states [80]. Even though consciousness is
a cortical phenomenon, the facial muscle activity is controlled by the brainstem [81]
(see figure 4).
The electrical activity of muscle contractions can be measured with electromyog-
raphy (EMG) [82]. Frontal electromyography (fEMG) can be used to detect patient’s
responsiveness to ambient and internal stimuli by measuring the electrical activity of
frontal facial muscles with three electrodes (see figure 5). Edmonds and colleagues
have demonstrated that painful and/or stressful stimuli increases fEMG amplitude
in conscious and lightly anesthetized patients, [83] and sudden fEMG activity has
been associated with increased patient responsiveness [84].
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Figure 4: Wakefulness and facial muscle responses are controlled by the brainstem,
whereas consciousness requires cortical activity, and reflex movements are controlled
at spinal level.
Figure 5: Electrode setup. Numbers 1 and 2 denote the active electrodes; G represents
the ground electrode. Modified from publication by Lapinlampi et al. [85].
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The fEMG signal is affected by the following factors in ICU setting: 1) the intensity
and frequency of stimuli caused by patient care and the underlying condition; 2) the
sedative and analgesic drug received by the patient; and 3) the effect of the illness
and drug treatment on brain and muscle functions, specifically encephalophathy,
delirium and use of neuromuscular blocking agents (NMBAs), which may alter the
fEMG responses to stimuli. [85]
3.2.2 Algorithm
Responsiveness Index algorithm quantifies the fEMG responses in relation to ambient
(light, noise, care procedures) and internal (pain, agitation) stimuli by giving out a
single number from 0 (unresponsive) to 100 (fully responsive) describing the strength
of the response. As the ambient and internal stimuli varies over time in the ICU
patients, the RI is hypothized to be a dynamic variable representing the balance
between stimulation and sedative drug effect [79]. No active stimulation is required,
because the patients are constantly stimulated in the ICU environment by light,
noise, and care procedures.
The RI algorithm development was performed in three stages. First, the fEMG
activity related to standard vocal stimulus in ICU patients was characterized. The
vocal stimulus used was a command of "open your eyes" with 80-dB intensity. The
response was considered positive if the patient opened his or her eyes within 10 seconds
after the stimulus. The epochs containing fEMG waveform starting 2 minutes before
and ending 2 minutes after the stimulus were extracted. The epochs were divided to
0.5-s windows and estimate of the fEMG power was calculated. The fEMG powers
were analyzed separately for patients who had positive response and negative response.
Median and the interquartile ranges were calculated from signal powers to describe
the form of typical fEMG response to vocal stimulus. After this, the algorithm was
developed in iterative process by using the characterized data. Finally, the algorithm
was evaluated against modified Ramsay Sedation Scale which used standardized
vocal, loud vocal (similar to standardized, but louder), and tetanic stimuli. [85]
The algorithm calculates root mean square power in 5-second epochs from fEMG
using 50–150-Hz frequency band. Before the power calculation, fEMG signal is
filtered with high-pass finite impulse response filter and 10-Hz comb filter, which
attenuates the mains frequencies and 10-Hz multiples. The filtering removes artefacts
caused by movement and blinks, which operate on low frequencies. Then, the power
value time series is processed with a filter that extracts the patient response related
steep rises. The RI value at time t can be expressed with the following equation:
RI(t) = S
(
t∑
n=t−N
g(n)log
(
PF(n)
1µV + 1
))
, (1)
in which the filtered power value at time point t is marked with PF. The scaling
function is denoted with S, which scales the RI value to range between 0 to 100. The
weighting function g operates as a low-pass filter and gives more weight to recent
fEMG changes. The 1µ sets the minimum value of logarithm to zero. N is the
number of PF values in the summation and it has been set to 720 samples, which
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corresponds to 1 hour. [85] The reason for setting N = 720 samples was, that in
order to measure the responsiveness level of the patient in a reliable manner, a longer
measurement period was needed.
(a)
(b)
(c)
Figure 6: (a) The fEMG power, (b) the RI value in figure, and (c) the corresponding
modified Ramsay score. Modified from publication by Lapinlampi et al. [85].
3.2.3 Intended use
Responsiveness Index is not intended to replace the role of clinicians in making
patient specific sedative administration decisions in the ICU. It is also not designed
to replace the current sedation practices. The clinical benefit of RI may be that it
provides additional information to the clinician and supports the decision making
process of administration of sedatives when used as an adjunct to other parameteres.
RI measurement has some limitations. The RI value is subject to individual
patient differences, and therefore, the RI target level for optimal sedation should be
adjusted individually for each patient. In addition, RI measurement does not work
with patients that are receiving neuromuscular blocking agents (NMBAs), since the
facial muscle reactions are blocked. In these cases, the RI value will remain low and
might give the user an inaccurate view of patient’s sedation status. As the drug
effect is terminated, the measurement starts working reliably again.
3.3 Hypothesis testing
Pilot trials are not used as conclusive evidence to support the safety and efficacy
claims of the device. The objective of a pilot trial is to study the feasibility of an
approach that is intended to be used in a pivotal study. [12, 13]
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As the sample sizes in pilot trials are small, they are not ideal for hypothesis
testing [12]. However, pilot studies can be used to look for trends, but the results
should be interpreted with caution. The statistical testing for continuous variables
in a pilot trial can be performed with non-parametric methods, such as Wilcoxon
rank-sum test. For categorial data, Fisher’s exact test can be used to explore the
association between the categories when sample sizes are small. Kaplan–Meier curve
with Logrank test is a viable option for time-to-event analysis when censoring is
required. These tests are briefly presented in the following subchapters.
3.3.1 Wilcoxon rank-sum test
Wilcoxon rank-sum test can be used to perform non-parametric analysis to test the
null hypothesis of variables which are not normally distributed. The null hypothesis
is that the samples come from the same population. [86]
First, Wilcoxon rank-sum test ranks all the observations as if they were from a
single sample. The smallest value has the rank value 1, and 2nd smallest rank value
2, and so on. Then, the sum of the ranks is calculated for both groups. By taking
account the number of samples in both groups and the sum of ranks of the group
where n is smaller, the p-value can be defined from Wilcoxon rank-sum distribution
table. [86]
3.3.2 Fisher’s exact test
Fisher’s exact test is used for hypothesis testing of contingency tables (see table 8)
when sample sizes are expected to be small. It explores the association of categorial
data of paired observations by giving out a p-value. The null hypothesis tested is
that there is no association between the groups and the categories.
Table 8: Example of a 2 × 2 contingency table.
Trial Control Row total
Yes a b a + b
No c d c + d
Column total a + c b + d a + b + c + d
The propability of obtaining a set of values with cell frenquencies a,b,c, and d
when null hypothesis is true is given by
p = (a+ b)!(a+ c)!(b+ d)!(c+ d)!
N !a!b!c!d! (2)
where N is the sum of cell frequencies a, b, c, and d.
3.3.3 Kaplan–Meier curve and Logrank test
Kaplan–Meier curve illustrates the propability of occurence of defined event as a
function of time. It can be used to compare the time-to-event of patients between
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the groups. The curve is plotted as a step function, in which each step corresponds
to one patient’s time-to-event. The events can be censored to indicate that the time
of event occurence cannot be accurately determined. Censoring is done, when the
required data are not available or the study period ends before the subject went
through the defined event. [86]
The comparison of statistical difference of the Kaplan–Meier curves can be
performed by using Logrank test. It is a non-parametric method for testing whether
or not the groups are samples from same population with respect to patients’ time-
to-event. The method ranks all event occurence times (excluding censored), and
produces an observed (O) and expected (E) number of events for both groups. Using
these variables, the chi-square (X2) can be calculated, which is a measure of the
degree of deviation between the observed and expected result:
X2 = (Oa − Ea)
2
Ea
+ (Ob − Eb)
2
Eb
, (3)
in which a signifies values of group a, and b signifies values of group b. By
comparing the result of X2 to chi-squared distribution χ2 with one degree of freedom,
the p-value can be defined. [86]
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4 Materials and methods
A randomized controlled pilot trial was performed to assess the effectiveness and safety
of continuous RI monitoring during early ICU care as nurse decision-support tool. The
study took place in an 18-bed Scottish general adult ICU admitting approximately 650
ventilated medical, surgical, and trauma patients annually (excluding routine cardiac
surgery and neuro-intensive care). Patients requiring mechanical ventilation and
sedation were randomized via sequential sealed envelopes following ICU admission.
The trial group patients received RI-augmented sedation monitoring and control
group patients were treated according to current practice. In trial group, the RI
monitoring was visible and the caregiving staff were asked to adjust sedation to
maintain a state where RI ≥ 20 and patient responds to verbal stimulation. In control
group, the RI monitor was connected to the patients but the data were concealed
from clinical staff.
For the RI monitor to demonstrate proof of concept and acceptability, the patients
who received RI monitoring were expected to spend more time with higher RI values.
To explore this hypothesis, the trial group patients were compared to control group
patients in terms of proportion of RI < 20. In addition, the groups were compared in
terms of incidences of deep sedation (proportion of time with RASS ≤ –4), the time
to reach RI ≥ 20 and RASS > –4, and patient outcomes. The patient outcomes were
defined as the number pre-defined adverse events; the time to reach first extubation;
the administered dose of sedative and analgesic drugs; the use of sedation holds;
ICU-LOS; and number of deaths.
In the secondary analysis, two patient subgroups were analyzed. The first
subgroup consisted of patients with RI < 20 at the start of monitoring and the second
subgroup consisted patients who were deeply sedated at the start of monitoring. The
hypothesis in the secondary analysis was that the effects of RI monitoring would be
more visible in these subgroups, as the nurses were only asked to alter the sedation
when RI was < 20 and the patient did not respond to verbal stimulus.
4.1 Patient enrollment and randomization
A total number of 90 ICU patients were enrolled into the study. The patient data set
was gathered in Royal Infirmary of Edinburgh ICU between 2009 and 2010. Patients
were screened by the clinical nursing staff with following inclusion criteria:
1. patients mechanically ventilated via endotracheal tube; and
2. patients receiving intravenous sedation with a hypnotic agent (midazolam or
other benzodiazepine) or propofol by continuous infusion.
Only mechanically ventilated patients were considered eligible, because excessive
sedation is common among these patients [79]. The exlusion criteria for this study
were
1. primary intracerebral disorder;
2. head injury (causing reduced conscious level prior to intubation);
26
3. patient who was already conscious at the time of enrolment defined as RASS
≥ −1;
4. less than 16 years of age;
5. patient not expected to survive the next 24 hours;
6. patient was receiving long term ventilation prior to ICU admission;
7. patient had a long term tracheostomy prior to ICU admission;
8. patient transferred, sedated and mechanically ventilated from another ICU
(unless recruitment possible within 24 hours of first ICU admission);
9. patients receiving continuous neuromuscular blocking agent at the time of
screening;
10. Previous enrollment in the trial;
11. status epilepticus;
12. confirmed meningitis or encephalitis; and
13. a known chronic neurological disease interfering with normal neuromuscular
functions.
The patients were divided into trial group (n = 44) and control group (n = 46) at
time of ICU admission. Patients in trial group received care based on the hospitals
current practice plus responsiveness monitoring, while patients in control group only
received care based on current practice. The current practice was intended to be
consistent with recommended best practice, including daily sedation holds and use
of a clinical sedation scale linked to decision-making strategy.
A major focus of this study was in the first 48 hours of intensive care, so the
patients were entered to the trial from the time of ICU admission and the consent
from relatives was obtained retrospectively. The patients were randomized to trial
and control group by using sealed envelopes immediately after the ICU admission.
4.2 RI monitoring in trial group
Responsiveness Index monitor was attached to the patient and data was presented
to the clinical staff continuously. All participating nursing staff received pre-trial
training in the study protocol and to the use of RI monitor.
The monitor presented a continuous trend over time that was color coded using
a traffic light system. A RI number was also recorded representing the most recent
value in a separate window. The monitor gave instructions based on the current RI
value. An example of a monitoring window is shown in table 9. Prompts accompanied
the color of RI presented on the screen, to encourage sedation reduction for patients
with a low RI values.
The pre-trial training included introduction to the concept that low RI values
are expected for deeply sedated patients, as well as some cases with coma unrelated
to sedation, and during natural sleep. Nurses were also instructed not to use the
monitor data when patients received neuromuscular blocking agents. Nurses were
asked to alter sedation using clinical judgement to transition patients out of the red
RI range and adjust sedation to achieve values in the amber/green range.
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Table 9: RI monitoring screen.
Monitor color Monitor instruction on screen Corresponding RI value
Green Ensure adequate analgesiaContinue current sedation unless patient agitated > 40
Amber
Moderate risk of oversedation
Text below box:
Ensure adequate analgesia
20–40
Red
High risk of oversedation
Text below box:
Ensure adequate analgesia if responsive to stimuli,
eg suctioning/physiotherapy
Reduce sedation dose if no eye-opening to physical
stimuli
< 20
4.3 RI monitoring in control group
All patients in control group were attached to responsiveness monitor, but the data
were blinded from clinical staff. RI data could only be accessed by code, which was
not available to the care providers.
4.4 Conditions to disconnect or reattach responsiveness
monitor
Responsiveness Index monitoring was used continuously until one of a pre-defined set
of criteria to discontinue was met. The monitoring was discontinued for the following
reasons:
1. 48 hours were elapsed from ICU admission or from first intubation;
2. the patient was extubated;
3. the patient died;
4. the patient was transferred to another ICU;
5. relative consent was declined; or
6. decision was made to withdraw from treatment.
Clinical staff was able to discontinue RI monitoring during care procedures or other
reasons according to clinical judgement. In these cases, monitoring was reattached
as soon as feasible.
The aim was to use RI monitoring whenever the patient was intubated and intra-
venous sedation was administered. The monitoring was continued during temporary
sedation stops that were part of the standard care procedure.
4.5 Recording RASS scores in trial and control group
The care giving nurse performed hourly sedation assessment by using RASS scoring.
The results were entered to the patient’s clinical research file. If the nurse was not
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able to perform the scoring or the patient was sleeping, then RASS scoring was not
performed in that particular hour. No trial specific instructions regarding sedation
titration was linked to RASS scoring and nurses were able to modify dosing based on
forms of routine and part of usual practice. RASS scoring was continued throughout
the monitoring period unless the patient died or a decision to withdraw treatment
was made or the patient was discharged from the ICU.
4.6 Daily data collection
Besides continuous recording of RASS scores and RI values, the following data were
collected on a daily basis:
1. Total sedative dose:
• propofol
• midazolam
• other
2. Total opiate dose:
• morphine
• alfentanyl
• other
3. Use of formal sedation holds
4. Extubation times
5. Occurence of following pre-defined sedation related adverse events:
• unplanned extubation (self-extubation)
• unplanned removal of vascular catheter
• unplanned removal of nasogastric/enteral tube
• episode of myocardial ischaemia
• myocardial infarction
• episode of agitation requiring bolus treatment (rescue medication)
4.7 Preprocessing RI values
Periods where Neuromuscular blocking agents (NMBAs) were administered plus 30
minutes after were removed from RI data if the monitoring was on. NMBAs were
administered to 13 patients. One patient received NMBAs in two occasions. In 10
patients, RI monitoring was on when the NMBAs were administered (n = 6 in the
trial group and n = 4 in the control group).
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Table 10: Occurence of NMBA administration during the intervention period and
removal of RI data.
Trial group
Patient ID Date Start time Stop Time Monitor status Removed period
002 2009-12-10 15:45 15:45 Monitoring ended Nothing removed
003 2010-01-08 13:00 13:30 Monitor attached 13:00 – 14:00
020 2010-03-05 03:05 03:08 Monitor attached 03:05 – 03:38
020 2010-03-05 05:50 05:53 Monitor attached 05:50 – 06:23
027 2010-03-10 17:20 17:20 Monitor attached 17:20 – 17:50
033 2010-03-20 14:00 16:30 Monitor attached 14:00 – 17:00
045 2010-04-09 16:15 Not reported† Monitoring not started Nothing removed
072 2010-06-13 23:05 23:10 Monitor active 23:05 – 23:40
081 2010-06-30 13:30 13:30 Monitor active 13:30 – 14:00
Control group
021 2010-03-05 22:00 22:05 Monitoring not started Nothing removed
024 2010-03-09 17:15 17:15 Monitor attached 17:15 – 17:45
040 2010-04-04 21:00 21:30 Monitor attached 21:00 – 22:00
043 2010-04-06 15:45 15:50 Monitor attached 15:45 – 16:20
044 2010-04-09 15:40 15:50 Monitor attached 15:40 – 16:20
† Stop time of NMBA administration was not added to patient’s clinical file, but it was noted that
NMBA administration stopped before the monitoring started.
4.8 Preprocessing RASS scores
RASS scores were preprocessed with the following algorithm:
1. If RASS scoring was not performed during a particular hour, the next RASS
value was included in the analysis.
2. In a situation where the next RASS score did not exist within one hour, the
RASS score from previous hour was taken.
3. If both, the next and the previous RASS values were missing, then the RASS
value of that specific time point was considered as missing.
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Figure 7: Illustration of RASS score preprocessing. At time points 2h and 4h, RASS
scoring was not performed, and the neighbor RASS score was copied. At time points
2h, 3h, and 4h, RASS scoring was not performed, thus time point 3h was considered
as missing.
4.9 Administration of drugs during study
The clinical team made decision of choise and administration of sedatives and analgesic
drugs. The standard sedative drug was propofol, and analgesic was alfentanil, at
the time of the study. Clinicians used alternative agents, principally midazolam and
morphine, according to clinical discretion. All decisions about other aspects of usual
care were made by the clinical team. The only trial-specific interventions related to
changes in the dose of sedatives was made by the bedside nursing staff.
4.10 Analysis
The effects of Responsiveness monitoring during the intervention period and after 7
days were explored by using several methods. The intervention period was defined
as the time from start of Responsiveness monitoring until 48 hours had elapsed from
ICU admission.
Primary analysis was performed for all patients. The secondary analysis was
performed for patients with baseline RI < 20 and for patients with baseline RASS ≤
–4. The RI value at baseline was defined as the first valid RI value (RI value after 30
minutes from start of monitoring). RASS score at baseline was defined as the first
RASS score after the start of RI monitoring.
All the analyses were performed using MATLAB (version R2014b) with Statistics
Toolbox and R (version 3.2.1).
4.10.1 Baseline differences
In order to test baseline differences between the groups, the following data were
recorded:
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1. age;
2. gender;
3. time from intubation to start of monitoring;
4. RI value at baseline;
5. RASS score at baseline; and
6. total intravenous sedation and analgesic drug dose prior to monitoring.
The patient groups were also compared at baseline in terms of severity-of-illness
scores. The following scoring systems were used: Acute Physiological and Chronic
Health Evaluation (APACHE II score), Charlson Comorbidity Index, and Sequential
Organ Failure Assessment (SOFA) score. In this study, SOFA scoring for central
nervous system was omitted because in sedated patients it is unreliable. Therefore,
the maximum SOFA score was 20.
4.10.2 RI values and RASS scores
Since RI value measures the patient responsiveness to ambient and internal stimuli,
RI values were expected to be lower during night when patients are asleep and
less care procedures are performed by the caregiving staff. Additionally, the RASS
scores were expected to be lower during the night as the nurses may administer more
sedatives to help the patients to sleep. In this study, night time was defined as the
time between 22:00-08:00 and day time as the time between 08:00-22:00. First, RI
values and RASS scores recorded at night time were compared to the RI values and
RASS scores recorded at day time. Second, the groups were analyzed in terms of
whether or not they had similar proportions of day and night RI values and RASS
scores. As RI uses 720 samples (corresponding to 1 hour) to calculate the RI value,
therefore the RI values are not independent of each other. Hence, in this comparison,
a RI sample from each hour from each patient was used. This analysis was done
in order see if the comparison of groups was affected by the possible day and night
variation.
Descriptive analyses for the time evolution of RI values and RASS scores were
performed to compare the differences between the two groups in defined time points
during the intervention period. The motivation for the time evolution analyses was
to find the time period when the RI monitoring was most effective. Two factors were
identfied which can distort the time evolution analyses of RI values and RASS scores:
1. RI values and RASS scores were expected to vary between day and night.
2. RI values and RASS scores were expected to be lower during early phase of
monitoring. The reason is that RI monitor was attached as soon as possible
after the patient was intubated. Patients are expected to require more sedatives
in the early phase of the mechanical ventilation when endotracheal tube has
recently been installed.
Therefore, the time evolution analyses of RI values and RASS scores were per-
formed using two different methods. In method one (time of the day RI and RASS
evolution), the day and night variation of RI values was taken into account when
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comparing the values between the groups. The analysis was done as follows for the
RI values:
1. The intervention period was divided into four-hour time intervals ranging from
00:00 to 24:00.
2. RI samples were selected from each patient every four-hours after recruitment
until the end of the intervention period.
3. The number of patients in each RI category was calculated in each four-hour
time interval. The categories were red (RI < 20); amber (20 ≤ RI ≤ 40);
green (40 < RI ≤ 100); and RI monitor off and intubated. Additionally, the
number of patients in whom RI monitoring discontinued due to extubation or
death were included in the analysis. This means that there were six different
categories which were RI < 20; 20 ≤ RI ≤ 40; 40 < RI ≤ 100; Extubated;
Died; and RI monitor off and intubated.
4. A stacked histogram was created to compare number of patients in each category
in given times of the day. As the intervention period lasted up for 48 hours,
and first RI value was taken between 00:00 and 24:00, the histogram covers RI
values for a period of 72 hours.
A histogram was also created for the RASS scores taken during the intervention
period by using the same method, but without adding the number of patients
extubated. The categories for RASS were RASS ≤ –4; RASS = –3; 0 ≥ RASS ≥ –2;
and RASS ≥ 1.
In method two, the time evolution of the RI values and RASS scores during
the intervention period were analyzed as a function of time elapsed from start of
monitoring. A sample from every four-hours from each patient was used. For RI
values, a box plot and stacked histogram were created to allow the comparison of the
values between the groups in each time point. The time evolution of RASS scores
were illustrated with a histogram showing the number of patients with each RASS
score every four-hours during the intervention period. Additionally, a histogram
showing the proportion of RI and RASS samples taken during night in each time
point was created.
The groups were also compared in terms of time to reach first RI ≥ 20, and time
to reach first RASS > –4 by using the Kaplan–Meier curve.
Finally, the differences between the groups at the end of the intervention period
were analyzed with respect to proportion of time spent on each RI category and
extubated, and proportions of RASS scores.
4.10.3 Patient outcomes
The groups were also compared in terms of patient outcomes. The compared patient
outcome variables after the intervention period were
1. total sedative and analgesic drug doses;
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2. number of patients who went through sedation hold;
3. number of patients extubated;
4. number of patients who died; and
5. number of pre-defined adverse events.
The compared patient outcome variables after 7-days following randomization
were
1. time to first extubation;
2. number of patients extubated;
3. number of patients who died;
4. number of patients discharged from the ICU;
5. number of patients still in the ICU;
6. number of patients still in the ICU receiving mechanical ventilation; and
7. number of patients transferred to another ICU.
4.10.4 Secondary analysis
In the secondary analysis, only the patients who had baseline RI < 20, and the
patients who had baseline RASS > -4 were analyzed. The comparison of trial and
control group was performed in terms of
1. proportion of RI < 20 and RASS ≥ –4 after the intervention period;
2. RI values and RASS scores at baseline; and
3. total sedative and analgesic drug doses during the intervention period.
4.10.5 Hypothesis testing
Due to small sample size, the continuous variables were not expected to be normally
distributed. The hypothesis testing for the non-parametric variables was performed
with Wilcoxon rank-sum test. Fisher’s exact test was used for all categorial data.
Survival analysis using Kaplan-Meier curve and Logrank test were performed for
time-to-event variables. A p < 0.05 was considered statistically significant.
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5 Results
5.1 Baseline characteristics
A total number of 74 patients (n = 36 in the trial group and n = 38 in the control
group) out of 90 were included in the analysis. 16 patients were excluded from the
study due to following reasons: no consent (n = 11), died before consent (n = 1),
missing envelope (n = 2), or the monitoring was not started (n = 2). Patients’
charasteristic data are listed in Table 11. The patient groups were similar at baseline
with respect to all measured variables.
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Table 11: Patients’ characteristics at baseline.
Group Hypothesis test
Baseline variable Trial Control p-value
Number of patients 36 38 NA
Age in yrs, median (1st, 3rd quar-
tile; min-max)
60 (44, 69; 25 – 85) 59 (43, 72; 27 – 80) 0.725W
Sex, male/female 21/15 26/12 0.469F
APACHE II score, median (1st,
3rd quartile; min-max)
20 (11, 24; 0 - 31) 23 (17, 26; 0 - 38) 0.083W
Charlson Comorbidity Index, me-
dian (1st, 3rd quartile; min-max)
1 (0, 2; 0 - 5) 1 (0, 2; 0 - 7) 0.835W
SOFA score from the first 24 hours,
median (1st, 3rd quartile; min-
max)
7 (5, 11; 2 - 16) *n=35 8 (5, 9; 1 - 16) *n=37 0.847W
RASS score at start of intervention
period, median (1st, 3rd quartile;
min-max)
-3 (-4, -2; min= -5, max=0) -4 (-4, -3; min= -5, max=2) 0.695W
Number of patients who had valid
RASS score at study entry, n (%)
27 (91.7%) 31 (92,1%) 0.578F
RI at start of intervention period,
median (1st, 3rd quartile; min-
max)
16 (0, 55; 0 – 100) 18 (0, 42; 0 – 100) 0.589W
Red, n (%)
Amber, n (%)
Green, n (%)
No value, n (%)
19 (54.3%)
5 (14.3%)
11 (31.4%)
1 (2.8%)
20 (54.1%)
8 (21.6%)
9 (24.3%)
1 (2.6%)
1.000F
0.545F
0.604F
1.000F
Time (in hrs) from intubation to
start of monitoring, median (1st,
3rd quartile; min-max)
4.0 (2.1, 6.2; 1.0 - 12.0) 4.9 (3.5, 7.7; 0.7 - 11.8) 0.193W
Total propofol dose (in mg) prior
to monitoring, median (1st, 3rd
quartile; min-max)†
205 (140, 720; 0 - 7200) 430 (170, 780; 0 - 2360) 0.327W
Total alfentanil dose (in mg) prior
to monitoring, median (1st, 3rd
quartile; min-max)‡
1.75 (0.75, 5.25; 0.00 - 14.00) 3.00 (1.00, 7.50; 0.00 - 17.50) 0.190W
W Wilcoxon rank-sum test p-value
F Fisher’s exact test p-value
* SOFA scoring was not performed for all the patients during the first 24 hours of ICU care.
† 1 mg of midazolam was considered equivalent to 10 mg of propofol. Two patients received
midazolam (n = 0 in trial group and n = 2 in control group).
‡ 1 mg of morphine was considered equivalent to 100 µg alfentanil. One patient in control group
and none of the patients in trial group received morphine.
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5.2 RI values
5.2.1 Day and night analysis
Comparison of day and night RI values (Figure 8) shows tha thet RI values were
lower during night time when less care procedures were performed and patients were
sleeping. The median RI value during day time was 29 (n = 1246) and during night
time 19 (n = 889). The difference was statistically significant (Wilcoxon rank-sum
test p < 0.001). According to Table 12, both groups had similar proportions of day
and night RI values.
Figure 8: Difference in day and night RI values. The values were independent, as
one RI sample from each hour from each patient was used. Cross-line within box
indicates median and + value is mean, while the upper box limit is 3rd quartile and
lower box limit is 1st quartile. Whiskers represent the range between 9 – 91%. A
p-value < 0.001 is denoted with ***.
Table 12: Proportions of day time and night time RI values for both groups.
Day (08:00-22:00) Night (22:00-08:00)
Trial group 57.1% 42.9%
Control group 57.9% 42.1%
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5.2.2 Time-of-day RI evolution
Figure 9 compares of RI values between the groups at different times of the day. The
figure also displays if the patient was extubated or the RI monitor was off while the
patient was intubated. None of the patients died during the intervention period. The
first day shows the patient enrollment to the study. The valid data for comparison
start from the beginning of the second day, when all patients had been recruited.
The number of patients is declining during the third day, as 48 hours had elapsed
from ICU admission.
According to the same figure, trial group had less patients with red RI values (RI
< 20) compared to control group in all time intervals during the second day. The
proportions of patients in both groups with RI < 20 in each time interval during the
second day are listed in Table 13. Additionally, the figure indicates that the patients
in the trial group were extubated faster during the intervention period.
Figure 9: Time-of-day RI evolution. A RI sample was selected from each patient
every four hours after the start of monitoring. A maximum of 48 hours of data
were used for all patients. None of the patients died during the intervention period.
Left-hand side values belong to the trial group (solid bar lines) and right-hand side
values to the control group (bars outlined with ’- -’).
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Table 13: Proportions of patients with RI < 20 during the second day in each time
interval.
Time of day Trial group (%) Control group (%)
00:00-04:00 31.4 52.6
04:00-08:00 30.5 42.1
08:00-12:00 22.2 26.3
12:00-16:00 16.6 18.4
16:00-20:00 13.9 21.1
20:00-24:00 20.0 24.3
39
5.2.3 RI evolution as a function of time elapsed from start of monitoring
In Figures 10a and 10b, the evolution of RI values are illustrated as a function of
time elapsed from start of monitoring in four-hour time intervals. Figure 10c shows
the proportions of RI values taken at night in each time point.
Both Figures (figures 10a and 10b) show that the patients in the trial group had
higher RI values compared to the control group. The most notable difference between
the groups can be seen from baseline up until 24 hours has elapsed from start of RI
monitoring. Figure 10c does not indicate any major differences in the proportions of
RI values taken at night between the groups. Therefore, the higher RI values in the
trial group cannot be explained with the day and night variation of RI values.
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(a)
(b)
(c)
Figure 10: (a) RI time evolution box plot from start of monitoring to 48 hours.
Cross-line within box indicates median and + value is mean while the upper box
limit is 3rd quartile and lower box limit is 1st quartile. Whiskers represent the range
between 9-91%. (b) RI time evolution histogram from start of monitoring to 48
hours. Number of patients is declining due to following reasons: decision was made
to withdraw patient from treatment, patient was extubated, or 48 hours had elapsed
since ICU admission or intubation. Left-hand side values belong to the trial group
(solid bar lines) and right-hand side values to the control group (bars outlined with ’-
-’). (c) Proportion of RI values taken at night.
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5.2.4 Time to reach first RI ≥ 20
Figure 11 (Kaplan–Meier curve) shows the time from start of monitoring to first RI
≥ 20. According to the figure, patients in trial group reached first RI ≥ 20 slightly
faster than control group patients. However, the difference was not statistically
significant (Logrank test p = 0.428).
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Figure 11: Kaplan-Meier curve of time to reach first RI ≥20. Censored events are
marked with cross. One patient in control group never reached RI ≥ 20, and therefore
was censored. A total of 35 patients (n=17 in trial group and n=18 in control group)
were censored, because their baseline RI value was ≥ 20.
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5.2.5 Proportions of RI values after the intervention period
The proportions of time the patients spent on each RI category or extubated after
the intervention period are shown in Figure 12. The primary category of interest was
the proportion of time spent with RI < 20, and the other categories were plotted for
the sake of curiosity.
The figure shows that patients in trial group spent less time with RI < 20 (median
of 15.6% vs. 33.4%). However, the result was not statistically significant (Wilcoxon
rank-sum test p = 0.077), but can be considered as a clear trend towards significance.
Figure 12: Proportions of time the patients spent on each RI category or extubated
during the intervention period. Trial group values in left-hand side in blue and
control group values in right-hand side in red. Cross-line within box indicates median
and + value is mean while the upper box limit is 3rd quartile and lower box limit is
1st quartile. Whiskers represent the range between 9-91%. No statistical significance
is denoted with n.s..
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5.3 RASS scores
5.3.1 Day and night analysis
Day and night analysis of the RASS scores (Figure 13) shows that the RASS scores
were lower during the night time. The median RASS score during the day time was
–2 (n = 821) and during the night time was –3 (n = 509). This result was statistically
significant (Wilcoxon rank-sum test p < 0.01). Both groups had similar proportions
of RASS scores taken during the day time and during the night time (see table 14).
Figure 13: Differences in day time and night time RASS scores. A p-value < 0.01 is
denoted with **.
Table 14: Proportions day and night RASS scores for both groups.
Day (08:00-22:00) Night (22:00-08:00)
Trial group 64.8% 35.2%
Control group 59.4% 40.6%
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5.3.2 Time-of-day RASS evolution
Figure 14 shows the evolution of RASS scores in given times of day during the
intervention period. According to the figure, there were no differences between the
groups in number of patients with RASS ≤ –4 during the second day, when all
patients had been recruited to the study.
Figure 14: Time of day RASS evolution. A RASS sample was selected from each
patient every four hours after the start of monitoring. A maximum of 48 hours of
data were used for all patients. Number of patients monitored with RASS varies
between timepoints because RASS scoring could not be performed every hour by
the clinical staff or the patient was asleep. Left-hand side values belong to the trial
group (solid bar lines) and right-hand side values to the control group (bars outlined
with ’- -’)
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5.3.3 RASS evolution as a function of time elapsed from start of
monitoring
Figure 15a presents the evolution of RASS scores during the intervention period as a
function of time elapsed from start of monitoring. In figure 15b, the proportion of
RASS scores taken at night time in each time point are shown. The RASS scores at
baseline are the first RASS scores after the start of monitoring. The figure does not
indicate that patients in the trial group would have less incidences of deep sedation
(RASS ≤ –4). The number of deeply sedated patients clearly falls in both groups,
but there is no distinct difference between the trial and control group.
Figure 15b shows that the number of RASS scores taken at night time varied
between the time points. However, both groups had virtually the same number of
RASS scores taken at night time in each time point.
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(a)
(b)
Figure 15: (a) Evolution of RASS scores during the intervention period as a function
of time elapsed from start of monitoring. Number of patients monitored with RASS
varies between timepoints because RASS scoring could not be performed every hour
by the clinical staff or patient was asleep. Left-hand side values belong to the trial
group (solid bar lines) and right-hand side values to the control group (bars outlined
with ’- -’). (b) Proportion of RASS scores taken at night in given time points.
47
5.3.4 Time to reach first RASS > -4
The Kaplan–Meier curve (figure 16) shows the time from start of monitoring to first
RASS > –4. The figure does not indicate that there would be any difference between
the groups in terms of time to reach RASS > –4 (Logrank test p = 0.677).
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Figure 16: Kaplan–Meier curve for first RASS > –4. Censored events are marked with
cross. One patient in control group never reached RASS score > –4, and therefore was
censored. A total of 27 patients (n = 14 in the trial group and n = 13 in the control
group) had first RASS ≥ –4 after the start of monitoring, hence were censored.
48
5.3.5 Proportions of RASS scores after the intervention period
The box plot (Figure 17) shows the distribution of RASS scores among the patients
after the intervention period. According to the figure, both groups had similar
proportions of RASS scores. The primary category of interest was the proportion of
RASS scores ≤-4, and the other categories were plotted out of curiosity.
Figure 17: Distribution of RASS scores among the patients after the intervention
period. Trial group values in left-hand side in blue and control group values in
right-hand side marked with red.
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5.4 Summary of results for RI and RASS analyses
Table 15 summarizes the results of the RI and RASS analyses with hypothesis testing.
In conclusion, none of the measured parameters showed statistically significant results
with p-value < 0.05.
Table 15: Intervention period variables
Group Hypothesis test
Intervention period variables Trial Control P-value
Proportion of time during the interven-
tion period with RI < 20, median (1st,
3rd quartile; min-max)
15.6% (8.4%, 29.6%; 0.9% -
86.9%)
33.4% (10.4%, 53.8%; 0.0% -
85.6%)
0.077W
Proportion of incidences with RASS
score of –4 or –5 during the interven-
tion period, median (1st, 3rd quartile;
min-max)
11.9% (0.0%, 35.4%; 0.0% -
93.5%)
16.9% (2.7%, 36.2 %; 0.0% -
100.0%)
0.698W
Time (in hrs) from start of monitoring
to first RI ≥ 20, median (1st, 3rd quar-
tile; min-max)
0.09 (0, 2.22, 0.00 – 7.84) 0.33 (0.00, 3.08, 0 – NA) 0.428L
Time (in hrs) from start of monitoring
to first RASS > –4, median (1st, 3rd
quartile; min-max)
2 (0, 8, 0 - 43) 3 (0, 8, 0 - NA) 0.677L
W Wilcoxon rank-sum test p-value
L Logrank test p-value
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5.5 Outcome measures
5.5.1 Time to first extubation
The Kaplan–Meier curve (Figure 18) shows the time to first extubation for both
groups. The follow-up was done until 7 days (>168 hours) had elapsed from the
start of monitoring. The baseline was defined as the time when monitoring starts.
According to the baseline characteristics (Table 11), the time from intubation to start
of monitoring was similar in both groups, and therefore, the groups are comparable.
The curve indicates that the patients in trial group were extubated faster during
the intervention period, but the difference between the groups evens out after 72
hours, and the result was not statistically significant (Logrank test p = 0.517).
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Figure 18: Kaplan-Meier curve of time to first extubation. Censored events are
marked with cross. Three patients in control group were censored during the follow-up
time due to the following reasons: transferred to another ICU (n = 2) or self-extubated
(n = 1). For a total of 22 patients (n = 11 in the trial group and n = 11 in the
control group), the extubation time was over seven days (> 168 hours), and therefore
they were censored.
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5.5.2 Total drug doses during the intervention period
Figure 19 shows the distribution of administered drug doses for propofol and alfentanil
during the intervention period. All patients in trial group and 36 patients in control
group received propofol. Additionally, 33 patients in trial group and 37 patients in
control group received alfentanil.
For the purpose of reporting, 1 mg of midazolam was considered equivalent to 10
mg propofol. Four patients in trial group and four patients in control group received
midazolam. In addition, 1 mg of morphine was considered equivalent to 100 µg of
alfentanil. Eight patients in trial group and seven patients in control group received
morphine.
Minor differences can be seen between the groups in terms of drug doses. The
median value of total propofol dose during the intervention period was smaller in
trial group (1365 mg vs. 1730 mg). In addition, the median value of total alfentanil
dose during the intervention period was also smaller in trial group (23.4 mg vs. 25.2
mg). However, these results were not significant (Wilcoxon rank-sum test p=0.638
for propofol and p=0.698 for alfentanil).
(a) Propofol (b) Alfentanil
Figure 19: Distribution of total propofol and alfentanil doses during intervention
period.
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5.5.3 Summary of patient outcome results
Table 16 shows results of patient outcomes after the intervention period. No statisti-
cally significant results were found. In Table 17, the time to first extubation and
patient outcomes after 7 days are summarized. No significant differences were found
between the groups.
Table 16: Patient outcomes after the intervention period.
Group Hypothesis test
Outcome variables Trial Control p-value
Total propofol dose (in mg) during the intervention
period, median (1st, 3rd quartile; min-max) †
1365 (380, 2790; 50 - 8710) 1730 (620, 3260; 0 - 8630) 0.638W
Total alfentanil dose (in mg) during the intervention
period, median (1st, 3rd quartile; min-max) ‡
23.4 (9.0, 36.4; 0.0 - 51.5) 25.2 (8.6, 36.0; 0.3 - 87.0) 0.681W
Proportion of patients undergoing sedation hold
during the intervention period, n (%)
30/36 (83.3%) 33/38 (86.8%) 0.751F
Extubated, n(%) 17/36 (47.2%) 17/36 (44.7%) 1.000F
Died, n(%) 0 (0%) 0 (0%) 1.000F
Number of patients with any pre-defined adverse
events during the intervention period, n (%)
7/36 (19.4%) 5/38 (13.1%) 0.538F
Unplanned extubation 0 1 1.000F
Unplanned removal of vascular catheter 0 0 1.000F
Unplanned removal of nasogastric or other enteral
tube
1 0 0.487F
Unplanned removal of other drain or device 0 0 1.000F
Episode of myocardial ischaemia 0 0 1.000F
Myocardial infarction 0 0 1.000F
Episode of agitation requiring bolus treatment
(rescue medication)
6 4 0.510F
W Wilcoxon rank-sum test p-value
F Fisher’s exact test p-value
† 1 mg of midazolam was considered equivalent to 10 mg of propofol. Eight patients received
midazolam (n = 4 in the trial group and n = 4 in the control group)
‡ 1 mg of morphine was considered equivalent to 100 µg alfentanil. 15 patients received morphine
(n = 8 in the trial group and n = 7 in the control group)
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Table 17: Time to first extubation and patient outcomes after 7 days.
Group Hypothesis test
Outcome variables Trial Control p-value
Time (in hrs) from start of monitoring
to first extubation, median (1st, 3rd
quartile; min-max)
42.4 (14.7, 168.0; 2.0 - NA) 54.8 (22.8, 168.0; 1.78 - NA) 0.517L
Died, n (%) 1/36 (2.8%) 3/38 (7.9%) 0.615F
Discharged from ICU, n (%) 20/36 (55.6%) 18/38 (47.4%) 0.497F
Still in ICU, n (%) 15/36 (41.7%) 15/38 (41.7) 1.000F
Still in ICU receiving mechanical venti-
lation, n
15 15 1.000F
Transferred 0/36 (0%) 2/38 (2%) 0.494F
L Logrank test p-value
F Fisher’s exact test p-value
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5.6 Secondary analysis
A total number of 39 patients (n = 19 in the trial group and n = 20 in the control
group) had baseline RI < 20. Baseline RASS was ≤ –4 for 31 patients (n = 13 in
the trial group and n = 18 in the control group). A total of 18 patients (n =8 in the
trial group and n = 10 in the control group) had baseline RI < 20 and RASS ≤ -4.
In the subgroup, where the baseline RI < 20 (see table 18), the secondary analysis
reveals a statistical difference between the groups in terms of proportion of time
spent with RI < 20 (median of 16.1% in trial group vs. median of 51.4% in control
group, p = 0.016). Additionally, the trial group patients received significantly less
alfentanil during the intervention period (median of 21.2 mg in the trial group vs.
median of 32.2 mg in the control group, p = 0.011). The median total propofol dose
was > 50% smaller in trial group (1090 mg in the trial group vs. 2380 mg in the
control group), but this result was not statistically significant (p = 0.140).
Table 19 does not indicate that the groups were significantly different with respect
to any measured parameter in the subgroup where the baseline RASS score was ≤-4.
Table 18: Patients with baseline RI < 20.
Group Hypothesis test
Intervention period variables Trial Control p-value
n 19 20 NA
Proportion of time during the in-
tervention period with RI < 20,
median (1st, 3rd quartile; min-
max)
16.1% (11.4%, 45.4%; 2.4% -
86.9%)
51.4% (33.4%, 71.6%; 4.8% -
85.6%)
0.016W
RASS score at baseline, median
(1st, 3rd quartile; min-max)
-4 (-4, -3; min=-5, max=-2) -4 (-4, -3; min=-5, max=0) 0.759W
Proportion of incidences with
RASS score of –4 or –5 during
intervention period, median (1st,
3rd quartile; min-max)
46.6% (15.4%, 65.4%; 0.0% -
93.6%)
35.3% (9.6%, 72.3%; 0.0% -
1.0%)
0.632W
Total propofol dose (in mg) during
intervention period, median (1st,
3rd quartile; min-max) †
1090 (375, 2965; 100 - 7290) 2380 (1510, 3730; 60 - 8630) 0.140W
Total alfentanil dose (in mg) dur-
ing intervention period, median
(1st, 3rd quartile; min-max) ‡
21.2 (8.5, 27.9; 0.0 - 49.0) 32.3 (23.3, 49.8; 1.0 - 87.0) 0.011W
W Wilcoxon rank-sum test p-value
† 1 mg of midazolam was considered equivalent to 10 mg of propofol. Five patients received
midazolam (n = 2 in the trial group and n = 3 in the control group)
‡ 1 mg of morphine was considered equivalent to 100 µg alfentanil. Four patients received morphine
(n = 2 in the trial group and n = 2 in the control group)
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Table 19: Patients with baseline RASS≤-4
Group Hypothesis test
Intervention period variables Trial Control p-value
n 13 18 NA
Proportion of time during the in-
tervention period with RI value
<20, median (1st, 3rd quartile;
min-max)
21.4% (13.6%, 35.5%; 1.9% -
86.9%)
33.8% (13.6%, 56.3%; 0.0% -
85.6%)
0.412W
RI value at baseline, median (1st,
3rd quartile; min-max)
4 (0, 64; 0 - 96) 1 (0, 31; 0 - 100) 0.424W
Proportion of incidences with
RASS score of -4 or -5 during the
intervention period, median (1st,
3rd quartile; min-max)
32.1% (0.0%, 59.0%; 0.0% -
93.6%)
13.8% (0.0%, 30.6%; 0.0% -
77.8%)
0.555W
† Total propofol dose (in mg) dur-
ing intervention period, median
(1st, 3rd quartile; min-max)
1520 (385, 2623; 100 - 8710) 2155 (620, 4140; 0 - 8630) 0.589W
‡ Total alfentanil dose (in mg) dur-
ing intervention period, median
(1st, 3rd quartile; min-max)
22.5 (11.4, 35.1; 0.0 - 51.5) 21.8 (19.0, 36.5; 1.0 - 87.0) 0.810W
W Wilcoxon rank-sum test p-value
† 1 mg of midazolam was considered equivalent to 10 mg of propofol. Three patients received
midazolam (n=1 in trial group and n=2 in control group)
‡ 1 mg of morphine was considered equivalent to 100 µg alfentanil. Five patients received morphine
(n=3 in trial group and n=4 in control group)
Because the Table 18 revealed statistically significant results in the subgroup
where the baseline RI < 20, the patients were also studied in terms of differences
based on baseline RI (see Table 20). This was done in order to find out whether
or not patients with baseline RI < 20 had common factors that could be identified
in view of inclusion criteria for the pivotal trial. However, no common factors were
found as the Table 20 shows that patients who had RI<20 at baseline were similar
to patients with baseline RI ≥ 20 with respect to all compared variables.
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Table 20: Comparison of patients’ baseline characteristics with respect to baseline
RI.
Baseline RI Hypothesis test
Variables Baseline RI < 20 Baseline RI ≥ 20 p-value
Number of patients 39 35 NA
Age, median (1st, 3rd quartile;
min-max)
59 (43, 71; 25 - 85) 62 (45, 69; 35 -79) 0.693W
Sex, male/female 22/17 25/10 0.160F
RASS score at baseline, median
(1st, 3rd quartile; min-max)
-3 (-4, -2: min=-5, max=1) -3 (-4, -2: min=-5, max=2) 0.764W
Total propofol dose (mg) prior to
monitoring, median (1st, 3rd quar-
tile; min-max)†
370 (160, 575; 0 - 7200) 350 (150, 790; 0 - 1690) 0.867W
Total alfentanil dose (mg) prior
to monitoring, median (1st, 3rd
quartile; min-max) ‡
2.0 (0.6, 7.0; 0.0 - 17.5) 2.5 (1, 6.3; 0.0 - 15.5) 0.638W
W Wilcoxon rank-sum test p-value
F Fisher’s exact test p-value
† 1 mg of midazolam was considered equivalent to 10 mg of propofol. One patient with low baseline
RI and one patient with high baseline RI received midazolam prior to monitoring.
‡ 1 mg of morphine was considered equivalent to 100 µg alfentanil. One patient with low baseline
RI and none of the patients with high baseline RI received morphine prior to monitoring.
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6 Discussion
6.1 Main findings
As this was a pilot trial, statistically significant results were not expected to be found.
However, the results of the primary analysis showed a trend in favor of trial group in
terms of proportion of time spent on RI < 20, time to reach first RI ≥ 20, and time
to first extubation during the intervention period. Nonetheless, without knowing the
decision-making process of the practicioners that led to extubation, it is impossible
to determine whether the use of RI actually led to a possibly shorter extubation
times in trial group.
There were no differences between the groups in terms of pre-defined adverse
events. This result may verify that using RI according to the study protocol is
safe. However, the sample size was small and the sedation related adverse events do
not occur frequently, so therefore studies with larger sample size will be needed to
validate the safety of the use.
The time evolution analysis of RI revealed that RI values in trial group were
notably higher compared to control group values between baseline and 24 hours
after start of monitoring. This result indicates that the use of RI monitoring is most
beneficial during this time period. The clinical implication of the finding is that RI
can help to guide the caregiving staff to optimally sedate the patients early after
intubation when patients require high doses of sedatives.
No trend was found indicating that there would be any difference between the
groups in terms of RASS scores, and in times to reach first RASS > –4 during the
intervention period. This raises the question, why the trend could be seen in RI
values but not in RASS scores? The reason might be that the purpose of RASS and
RI are not identical, thus they cannot be compared. RASS relies on measuring the
effects of fixed stimuli in a discrete time point, while RI is a continuous retrospective
measurement of the patient’s responsiveness to ambient and internal stimuli.
The Kaplan–Meier curve (Figure 18) showed that some patients were extubated
very early after the start of monitoring. This means that these patients in trial
group were affected by the study protocol for only a little of time as RI monitoring
was removed from patients who were extubated. It can be assumed that these
patients also received only small doses of sedative drugs during the intervention
period, because they were quickly removed from mechanical ventilator. In conclusion,
if the patient only received small amounts of sedatives and spent only a short time in
mechanical ventilation, he or she was likely unaffected by the study protocol, because
the nurses did not have enough time to make decisions based on RI, and there were
not a high doses of sedatives from where to reduce.
6.2 A comparison to similar study done with BIS
The results of a similar study by Olson and colleagues [73] performed with BIS-
augmented sedation monitoring were briefly presented in Chapter 3.1.1. In the study,
Olson and the research team reported that using BIS as an adjunct to RSS (n =
58
32) compared to only using RSS (n = 35), decreased the amounts of administered
sedatives significantly (93.5 ml vs. 157.8 ml, p < 0.015). This raises the question why
in the study by Olson and colleagues the research team was able to have statistically
significant results in terms of drug doses and this study could not? This can be
expained with the following reasons:
1. The studied time period was different. Olson et al. used 12-hour measurement
period, and in this study the maximum time period of RI monitoring was 48
hours. The sedation monitoring might be most beneficial during the first 12 (or
maybe 24) hours after intubation, because during this time period the patients
need more sedatives. After this critical period, the sedation monitoring with
RI or BIS might be insignificant.
2. The sedation management and the quality of sedation management varies
between hospitals. In this study, the control group patients were treated
according to the defined best practice. The article published by Olson et al.
does not reveal, in detail, how the sedation management was performed in
patients who did not receive BIS agumented sedation monitoring. They only
disclose that these patients were monitored with RSS and the nurses were
instructed to adjust the sedation infusion to achieve RSS score of 4 (patient
asleep, brisk response to glabellar tap or loud auditory stimulus). A multicenter
trial would be needed in order to validly compare the study protocols and
performances of the monitors.
6.3 Secondary analysis
The secondary analysis revealed that the effects of RI monitoring were more visible
in the subgroup where baseline RI < 20. These patients spent more time with RI <
20 during the intervention period, and therefore, were more affected by the study
protocol. As a result, the patients in trial group received significantly less alfentanil
during the intervention period. Additionally, a clear trend was seen showing that
the patients in trial group received less propofol (p = 0.014).
In the subgroup where baseline RASS ≤ –4, no differences were found between
the groups with respect to any variable. The reason for this result might be that the
administration of sedatives was not primarily controlled with RASS.
It must be noted that the baseline characteristics of these two subgroups were not
analyzed. However, as these subgroups were taken from the same patient population,
the baseline characteristics were expected to be similar between the trial and control
group.
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6.4 Recommendations for pivotal trial
A flowchart of the recommended study protocol for the pivotal trial is showed in
Figure 20, and proposed treatment algorithm for trial group patients in Figure 21.
Few modifications are proposed to the protocol tested in this study.
Firstly, based on the result that the effects of RI monitoring are significant among
patients with baseline RI < 20, the primary analysis should be performed only for
this subgroup of patients. The patients who had baseline RI < 20 were more likely
to spend more time with low RI values, and therefore, were more affected by the
tested study protocol. The secondary analysis should be performed for all patients.
Secondly, based on the significant findings of this study, the main objective in
the pivotal trial should be to test whether RI-augmented group, compared to control
group, will receive significantly less sedatives and analgesics during the monitoring
period without excess adverse events. Therefore, the total sedative and analgesic
drug doses and the number of adverse events during the monitoring period should
be called the primary measures of the study. As the primary analysis and secondary
analysis of this thesis did not find any difference in terms of proportions of deep
sedation (RASS ≤ –4) between the groups, the primary measure in the pivotal trial
should not be the number of deep sedation incidences. Additionally, as RI does not
have a valid reference, and no study has yet done which would prove that RI is a
valid measure of sedation status, the primary measure of the pivotal trial should
not be the proportion of time spent on low RI levels. The secondary measures of
the pivotal trial should be the other patient outcomes explored in this pilot trial
with high priority in time to reach first extubation. The follow-up for the secondary
measures should be continued until at least 7 days has elapsed since ICU admission.
Thirdly, the time evolution analyses of RI showed that RI monitoring was most
effective between baseline and 24 hours. Therefore, the RI monitoring period should
be from start of monitoring until 24 hours has elapsed from ICU admission. This
study also showed that time from intubation to start of monitoring varied between
1.7 hours to 12 hours. The study protocol of the pivotal trial needs emphasize the
importance of starting the RI monitoring as early as possible after the intubation.
This way the nurses will receive RI-augmented sedation guidance during the period
which is the most critical in sedation management.
Lastly, as this study showed that RI monitoring does not increase the number
of sedation related adverse events, the patients in trial group should be treated
with sedation-reduction algorithm that could lead to more significant results. The
algorithm is described in figure 21. The objective of the algorithm is to reach and
maintain RI ≥ 40, and a state in which the patient responds to verbal stimulation.
Increasing the RI threshold value to 40 can be expected to be safe, as the sedation
is reduced also based on whether or not the patient responds to verbal stimulation.
Additionally, the algorithm has more structured approach to use the RI monitoring
by setting rules when to observe the RI value. This way the nurses cannot neglect the
RI monitor, and are obligated to use RI monitoring when treating the patients. The
waiting time after patient responds to verbal stimulation was set to 60 minutes so
that the patient would not be disturbed frequently. All cases in which the described
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algorithm cannot be followed should be reported.
The patients in the control group should be treated with the current hospital
policy, not with best practice. This way the study would reflect the benefits of
RI-augmented sedation monitoring in the most true setting.
The pivotal trial should aim to provide valid scientific evidence to support the
claim that the use of RI as an adjunct other sedation practices may be associated
with a reduction in primary sedative use during early intensive care.
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Assess eligibility at ICU admission
Mechanically
ventilated receiving
i.v. sedation?
Meets the exlusion criteria?
Exclude
Exclude
Randomize and attach to RI monitor
Control group Trial group
Treat according to
hospitals current practice
Treat according
to algorithm
(Figure 21)
Discontinue RI monitoring if 24 hours
has elapsed from ICU admission
Continue the follow-up until 7 days
has elapsed since ICU admission
Analyze results
Patients with
baseline RI < 20
All patients
Secondary analysisPrimary analysis
No
Yes
Yes
No
RI blinded RI visible
Record
primary
measuresRecord
secondary
measures
Figure 20: Flowchart of the proposed study protocol for the pivotal trial.
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Observe RI value
RI<40? Wait 60 minutes
Is the RI value growing?Wait 15 minutes
Does the patient respond
to verbal stimulation?
Reduce the amount of sedation
No
Yes
Yes
No
Yes
No
Figure 21: Treatment algorithm for trial-group patients.
63
7 Conclusion
In this Thesis, the objective was to assess the effectiveness and safety of continuous
Responsiveness Index-augmented sedation monitoring during early ICU care as a
nurse decision-support tool. In conclusion, the RI monitoring seemed to guide the
administration of sedatives and analgesics as RI values showed to be higher in trial
group. In addition, there were no excess adverse events, and therefore, the protocol
was safe for the investigated patients.
The results were promising. Multiple outcome measures indicated that RI moni-
toring might lead to better sedation outcomes without excess adverse events. However,
as this study had a small sample size, the results in the primary analysis were not
statistically significant, but a trend was found.
This study proved that the protocol could be used in the pivotal trial with few
modifications. It also supports the concept of RI-augmented sedation monitoring as
a tool to safely reduce the amount of sedative drugs administered to mechanically
ventilated patients. Additional studies with larger sample sizes will be needed to
fully determine the benefits and safety of using fEMG based monitors in sedation
management.
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